Literature DB >> 28879517

Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro.

Dan Wang1, Meihua Guo1, Jiawen Yu1, Xinying Wang1, Qian Zhang1, Xu Yang1, Jiaqi Li1, Chunhui Zhao2, Bin Feng3.   

Abstract

Glioma is a prevalent malignant primary brain tumor in adults, the treatment for which remains a challenge due to its high infiltration and recurrence. Hence, treatments that lead to the suppression of glioma cell migration and invasion may be used in addition to surgery to increase the therapeutic outcome. In this study, we aimed to construct a multifunctional protein that would exert an effect on glioma cell proliferation and migration. The protein is named GL1-P53C-11R and it consists of the glioma-targeting peptide GL1 (G), the P53 C terminus (Pc) and the cell-penetrating peptide arginine (R). GL1-P53C-R was expressed with the fusion protein ZZ and immunofluorescence analysis showed effective delivery of the fused ZZ-GL1-P53C-R protein represented as ZZ-GPcR. The ZZ-GPcR exhibited an inhibitory effect on the proliferation, migration and invasion of U87ΔEGFR cells. Western blotting results indicated that it caused significant changes in the expression levels of cell cycle and apoptotic proteins. Flow cytometric analysis showed increase apoptosis. Our findings suggest that the P53C in the fusion protein ZZ-GPcR can enter into glioma cells to exert its inhibitory effect.

Entities:  

Keywords:  Apoptosis; Cell proliferation; Glioma; P53 C terminus; Targeting peptide

Year:  2017        PMID: 28879517      PMCID: PMC5809644          DOI: 10.1007/s10616-017-0122-3

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  28 in total

1.  p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes.

Authors:  Pierre-Jacques Hamard; Dana J Lukin; James J Manfredi
Journal:  J Biol Chem       Date:  2012-04-18       Impact factor: 5.157

2.  Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133.

Authors:  Jun-Haeng Cho; A-Ru Kim; Sang-Heon Kim; Su-Jae Lee; Hoeil Chung; Moon-Young Yoon
Journal:  Acta Biomater       Date:  2016-10-06       Impact factor: 8.947

Review 3.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

4.  Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/cytoplasmic site of action in postnatal cortical neurons.

Authors:  Takuma Uo; Yoshito Kinoshita; Richard S Morrison
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

5.  Cell-penetrating D-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer.

Authors:  Daiji Araki; Kentaro Takayama; Miyabi Inoue; Toyohiko Watanabe; Hiromi Kumon; Shiroh Futaki; Hideki Matsui; Kazuhito Tomizawa
Journal:  Urology       Date:  2009-12-06       Impact factor: 2.649

6.  A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy.

Authors:  Si Chen; Lei Rong; Qi Lei; Peng-Xi Cao; Si-Yong Qin; Di-Wei Zheng; Hui-Zhen Jia; Jing-Yi Zhu; Si-Xue Cheng; Ren-Xi Zhuo; Xian-Zheng Zhang
Journal:  Biomaterials       Date:  2015-11-10       Impact factor: 12.479

7.  Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.

Authors:  Christina L Appin; Jingjing Gao; Candace Chisolm; Mike Torian; Dianne Alexis; Cristina Vincentelli; Matthew J Schniederjan; Costas Hadjipanayis; Jeffrey J Olson; Stephen Hunter; Chunhai Hao; Daniel J Brat
Journal:  Brain Pathol       Date:  2013-01-30       Impact factor: 6.508

8.  Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain.

Authors:  Jiawen Yu; Meihua Guo; Ting Wang; Xiang Li; Dan Wang; Xinying Wang; Qian Zhang; Liang Wang; Yang Zhang; Chunhui Zhao; Bin Feng
Journal:  Cell Prolif       Date:  2016-02-03       Impact factor: 6.831

9.  Emerging biomarkers in glioblastoma.

Authors:  Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Journal:  Cancers (Basel)       Date:  2013-08-22       Impact factor: 6.639

Review 10.  Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.

Authors:  Frederic Heitz; May Catherine Morris; Gilles Divita
Journal:  Br J Pharmacol       Date:  2009-03-20       Impact factor: 8.739

View more
  1 in total

Review 1.  Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas.

Authors:  Christy Kolsteeg; Esther Hulleman; John Bianco
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.